Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ.
Tizona develops next-generation immunotherapies
DescriptionIFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
Virion Biotherapeutics is a developer of biological antivirals creates to offer improved therapeutics for respiratory viral infections.
Wilson Therapeutics focuses on developing novel therapies addressing unmet medical needs in rare diseases.
VirionHealth is a biotechnology company
Kesios Therapeutics, a London, UK-based oncology drug discovery company
Abingworth has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Abingworth's top investment sectors include Biotechnology, Therapeutics, Health Care, Biopharma, Pharmaceutical. The firm invests across 17 different industry categories.
Among tracked funding rounds, Tizona Therapeutics received $300.0M in a Corporate Round round. Abingworth's total known invested capital is $5.2B.
Abingworth's average investment size is $105.8M across its portfolio of 49 companies.
Recent Abingworth portfolio additions include Anjarium Biosciences, R1 Therapeutics, Spruce Biosciences, Vera Therapeutics, Wugen. These companies were founded in 2020 or later.